USCWA
RVNC

U.S. Capital Wealth Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-250
Closed -$4.62K – 1572
2022
Q4 		$4.62K Buy
+250
New +$5.72K ﹤0.01% 1400

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

U.S. Capital Wealth Advisors's RVNC Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 250 shares — an estimated $4.62K sold.

U.S. Capital Wealth Advisors first reported a position in RVNC in Q4 2022 and held it in 1 quarter. The position peaked at $4.62K in Q4 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 250 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $4.62K.
  • U.S. Capital Wealth Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Revance Therapeutics, Inc. position peaked at $4.62K in Q4 2022.
  • 216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.